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peptide. Cy7-TCP-1 activity localized not only in metabolically active tumors, as defined by 18 F-FDG imaging, but also in peritumoral microvasculature. In conclusion, TCP-1 probes may have a distinct targeting mechanism with high selectivity for CRC and tumor-associated vasculature.
Molecular imaging with TCP-1 probes appears promising to detect malignant colorectal lesions.
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Introduction
Colorectal cancer (CRC) is the third leading cause of cancer death in men and women in the United States [1] . Patients with inflammatory bowel disease (IBD), especially those with longstanding and extensive colitis such as ulcerative colitis or Crohn's disease, are at increased risk of developing invasive CRC compared to healthy individuals [2] [3] [4] . Periodic endoscopic surveillance with biopsy is commonly used in these populations to detect CRC and reduce CRC progression and mortality [5] [6] [7] . However, in approximately 5-10% of cases, complete visualization of the colonic mucosa is not achieved [8] . Visible findings at colonoscopy may lack morphologic detail and molecular specificity, and a dysplastic lesion maybe difficult to distinguish from epithelial regeneration associated with inflammation. Dysplasia miss-rates with conventional colonoscopy have been reported as high as 22%. Thus, new imaging approaches with sensitive and specific molecular probes capable of differentiating colorectal CRC lesions from non-malignant lesions are clearly needed for early CRC detection [9] [10] [11] .
The cyclic peptide c[Cys-Thr-Pro-Ser-Pro-Phe-Ser-His-Cys]OH (c[CTPSPFSHC]OH, TCP-1) was originally identified in orthotopic mouse CRC using phage display selection [12, 13] . It is bridged by a disulfide bond from the side chains of cysteine termini. A search for the lowestenergy conformation of the TCP-1 amino-acid sequence using MacroModel computational Fig. 1 4 molecular modeling demonstrates that this cyclic peptide has a predominant β-sheet-like structure [14] , as shown in Fig. 1 , indicating that there is a relatively large binding region. In vitro and in vivo studies suggest that TCP-1 may have a unique ability to home to CRC neovasculature and deliver imaging agents and chemotherapeutic drugs to the tumor sites [12, 13, [15] [16] [17] . Cell imaging with TCP-1-conjugated quantum dots demonstrated that TCP-1 might localize in the nuclei [12, 13] . It is currently unclear if TCP-1 is a nuclear localization signal (NLS) peptide, in which a protein is tagged for import into the cell nucleus by nuclear transport [12, 13] 
Probe preparation
The TCP-1 peptide was commercially synthesized at AnaSpec, Inc. (Fremont, CA) according to our specifications. CysValGlnThrAlaGlnLeuLeuCys (CVQTAQLLC) peptide was prepared to provide a negative control for characterizing the specificity of TCP-1 targeting. The TCP-1 and CVQTAQLLC peptides were prepared at purity > 95% at 254 nm by analytical high performance liquid chromatography (HPLC) and conjugated with succinimidyl 6-hydrazinopyridine-3-carboxylic acid (S-HYNIC) [18] . Low-resolution mass spectrometry 
Radiolabeling TCP-1 with 99m Tc
Radiolabeling took place by adding pertechnetate ( Tc-CVQTAQLLC, were purified by reverse-phase (RP) HPLC using a C18 column with a gradient elution of 0.1% trifluoroacetic acid (TFA) in water for the A-solvent and 0.1% TFA in acetonitrile (ACN) for the B-solvent at a flow rate of 1 mL/min. After HPLC purification, radiochemical purity (RCP) was greater than 6 99% for animal administration within 1 hour. In vitro stability of the radiolabeled peptides in mouse serum was tested by incubating 37 MBq of the radiolabeled product in 0.4 mL of mouse serum at 37°C for 1 and 6 hours, respectively. Subsequently, the samples were centrifuged (4000 g, 4 °C) for 5 minutes, and 25 μL aliquots of the supernatant were analyzed by RP-HPLC [19] . 
Synthesis of

In vitro saturation binding assay
The HCT116 human colon-cancer cell line was obtained from American Type Culture Collection (ATCC) (Rockville, MD). On the day prior to the experiment HCT116 cells (10 6 cells per well) were plated in 24-well plates and incubated at 37 °C and 5% CO2 overnight. Cells were washed and media were replaced with binding media containing 1% BSA. Tc-TCP-1. After incubation at 37 °C for 2 hours, the supernatant was removed and the cells 7 were washed twice with 1 mL of ice-cold PBS (pH 7.4). The combined supernatants represent the free, unbound radiopeptide fraction. To determine cell-bound fraction, the cells were lysed with 1 M NaOH (1 mL) for 10 minutes at 37 °C and the wells were washed twice with 1 M NaOH (1 mL). The free and cell-bound fractions were measured in a gamma counter.
Dissociation constants (Kd) were calculated from the data for specific binding with nonlinear regression using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). Experimental conditions were performed in triplicate.
Xenografted tumor models and experimental groups
Severe Dorsal skinfold window chambers (DSWC) were established in eight SCID mice [20, 21] . For implantation of the chamber into the dorsal skin, the entire back of the animal was shaved and depilated, and two symmetrical titanium frames were imbedded so as to sandwich the extended double layers of skin; one layer of skin was removed in a circular area approximately 15 mm in diameter, and the remaining layer was covered with a circular cover-glass incorporated into one of the frames. HCT116 and HCT116/RFP cells expressing red fluorescent protein (RFP)
were implanted into the skinfold chamber to investigate the targeting selectivity of TCP-1 to the tumor lesion and tumor-associated vasculature by fluorescence imaging of Cy7-TCP-1. The cover-glass was carefully removed and cancer cells (2 μL, about 2×10 5 cells) were imbedded at the center of the chamber. A new cover-glass was then placed on the chamber. The tumors in the chamber model were grown for 5-7 days for imaging studies.
SPECT imaging of xenografted tumor models
Dynamic or static single-photon emission computed tomography (SPECT) images of all mice in Groups I-IV were acquired using a stationary SPECT imager, FastSPECT II [22] .
FastSPECT II provides dynamic imaging capabilities without rotation of either animals or detectors. Each animal was anesthetized with 1.0-1.5% isoflurane, loaded into the FastSPECT II imager, and positioned so that the tumor on the right shoulder and the control left shoulder were in the field of view of the imager. Tc-TCP-1 or control peptide (55.5-92.5 MBq, 0.2 mL) was
given by direct intravenous injection or administered using a pre-positioned catheter in the tail vein. Each mouse received approximately 1 µg HYNIC-conjugated peptide. In the Group I mice, dynamic SPECT list-mode projection data were collected every minute for 10 minutes immediately after tracer injection, followed by 5-minute projection data every 15 minutes up to 3
hours. All other mice in Groups II-IV were imaged once at 3 hours after tracer injection. Sixteen projections were obtained, one from each camera, to generate the data set for tomographic reconstruction. Reconstructions of FastSPECT II data were processed using 30 iterations of the maximum-likelihood estimation method (MLEM) algorithm. Tomographic transverse, coronal, and sagittal slices with one-voxel thickness (0.5 mm) were produced using AMIDE 1.0.4 software.
Imaging of DSWC models
Four mice with HCT116 xenografts in DSWC were imaged with 18 F-fluorodeoxyglucose ( 18 F-FDG) using a charged-particle imager. This imager was custom-built for imaging chargedparticles emitted from tissues of a living organism [20, 21] . It consists of an ultra-thin phosphor capable of imaging radiolabeled tracers in superficial or exposed tissues, a high-numericalaperture compound lens, and a cooled ultra-sensitive CCD camera. The mice were fasted for 6 hours before 18 F-FDG (37-74 MBq) was injected intravenously. A circular piece of phosphor was placed in direct contact with the xenografted tumor, vasculature, and skin within the chamber being imaged. Under anesthesia with 1.5% isoflurane, images of 18 F positron activity within the chamber were acquired for 5 minutes at 30-60 minutes after 18 F-FDG injection. Cy7-TCP-1 (25 µg, 0.2 mL) was intravenously injected in the same mice approximately 24 hours after 18 F-FDG administration. White-light photographic and Cy7-TCP-1 fluorescent images of tissues within the chambers were acquired using a Nikon E600 microscope (Nikon Instruments
Inc., Melville, NY) with an ICG filter (excitation 749 nm and emission 820 nm) for 5-8 seconds.
In order to further map the location of the tumor cells, tumor size, and vascular network related to TCP-1 uptake, Cy7-TCP-1 was injected and imaged using the ICG filter as described above in four anesthetized mice bearing HCT116/RFP xenografts, and then fluorescence of RFPexpressing tumor cells within the chamber was imaged using the same microscope with a DSRed2 filter set (excitation 558 nm and emission 583 nm) for 1-5 seconds.
Postmortem assays
All mice in Groups I-IV were sacrificed by barbiturate overdose at the end of the imaging session, and samples of tumor, blood, kidney, liver, heart, lung and skeletal muscle were harvested. The tissue samples were weighed and the radioactivity was measured by the CRC-15W Dose Calibrator/Well Counter (Capintec, Inc., Ramsey, NJ) to calculate the percentage of injected dose per gram of tissue (%ID/g). In the mice with DSWC, the titanium frames were removed and the skin with tumors inside the chambers was harvested. The tumors were excised and fixed in formalin-saline for 24 hours. After paraffin mounting, sections (5 µm) were cut, stained with hematoxylin and eosin (H&E), and examined microscopically.
Statistical analysis
All quantitative results were expressed as mean ± S.E.M. Comparisons between two variables were performed with one-way analysis of variance. Probability values less than 0.05 were considered significant.
Ethics
The animal experiments were performed in accordance with Principles of Laboratory Animal
Care from the National Institutes of Health (NIH Publication 85-23, revised 1985) and were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Arizona.
Results
Radiolabeling, in vitro stability, and cell binding
The labeling yield of the product was 92-95% and the radiochemical purity was greater than 99% after HPLC purification. A representative HPLC radiochromatogram of 
SPECT images of HCT116 and PC3 cancer xenografts
As shown in Fig. 4 , dynamic images of 99m
Tc-TCP-1 in the mice of Group I with HCT116 colon cancer xenografts demonstrated that the tumor could be initially localized by 15-30 minutes after injection and remained readily detectable at the end of the imaging session at 180 minutes. Relative to the animals with non-blockade (Fig. 5a) , in vivo blockade by unlabeled Tc-TCP-1 was administered in mice bearing human prostate cancer, images
showed that the radioactivity of the PC3 prostate cancer xenografts in Group IV animals was at the level of soft tissue background activity (Fig. 5d) .
Results of biodistribution measurements
Postmortem biodistribution measurements (%ID/g) are summarized in Table 1 . Tc-CVQTAQLLC inactive peptide showed significantly less radioactivity in the HCT116 tumors (P = 0.002), but higher blood activity (P < 0.001) and kidney uptake (P < 0.05) compared to animals in Group I that received Tc-TCP-1 in the xenografted PC3
prostate cancer was significantly lower than that in the HCT116 cancer (P < 0.001). The radioactive ratios of tumor to blood and muscle were statistically higher in the HCT116 tumors without blockade than that in the tumors of other three groups (P < 0.01, respectively). 
TCP tumor uptake in the DSWC model
White-light imaging of the DSWC showed the areas of implanted tumor cells and associated blood vessels ( Fig. 6a and d) . Capillaries near the boundary zone of the HCT116 tumor lesion were also visible. The area of active tumor metabolic activity, indicated by 18 F-FDG uptake (Fig. 6b) , was smaller than the anatomical lesion size delineated on the microscopic white-light image in Fig. 6a . In two of the four mice with HCT116 DSWC, the 18 F-FDG image taken by the direct positron imager revealed an annular shape of the radioactive accumulation, as in Fig. 6b . Subsequent pathological analysis indicated that the high 18 F-FDG uptake was associated with areas of dense and rapidly growing tumor cells. There were mismatches in Cy7-TCP-1 distribution on the fluorescence image (Fig. 6c) and 18 F-FDG uptake on direct positron image taken one day earlier (Fig. 6b) . Fluorescence microscopy demonstrated that the area of Cy7-TCP-1 uptake was larger than 18 F-FDG tumor uptake and covered both the tumor mass and a peripheral rim consisting of blood vessels, capillaries, and connective tissue. In the DWSC with implanted HCT116 cells expressing red fluorescent protein, the location and extent of Cy7-TCP-1 uptake (Fig. 6f) extended beyond the RFP-positive tumoral lesion (Fig. 6e) and corresponded to the extent of the anatomical lesion seen on white-light examination (Fig. 6d) .
Overall, the Cy7-TCP-1 activity was found to localize within the tumor lesion, peritumoral microvasculature, and some tumor-associated vessels, as illustrated on co-registered fluorescence and white light microscopic images in Fig. 6 a&c and d&f.
Histologic findings
H & E staining of the skin and tumor from the DWSC showed that the tumor was composed of hyperchromatic polyhedral, ovoid and spheroidal cells arranged in sheets. The tumor cells displayed fairly prominent nucleoli, high nuclear to cytoplasmic ratios and many mitotic figures.
The tumor boundary zone was composed of a mixture of newly formed blood vessels, collagen, and various stromal cells including adipocytes, fibroblasts, lymphocytes, mast cells, and 
Discussion
When TCP-1 was originally identified from mouse CRC, initial studies focused on evidence of TCP-1 targeting CRC vasculature [12, 13] . It was also found that TCP-1 was able to react with human CRC and target the blood vessels of human CRC samples. Although the specific target for TCP-1 has not been elucidated, it is possible that TCP-1 receptors are expressed on both CRC cells and stromal endothelial cells, since tumor cells, tumor-associated and tumorderived endothelial cells share biomarkers [23, 24] . The TCP-1 receptors may be unique to these neoplastic cells [13, 25, 26] , or they may be expressed at low levels in healthy tissues but shown by its higher blood retention and kidney uptake. This biodistribution difference might be due to different hydrophilic properties of these two peptides. It is also possible that the higher kidney accumulation resulted from absence of uptake of the inactive control peptide in the tumor, with increased peptide available for renal excretion.
Uptake of 99m
Tc-TCP-1 was prominently associated with areas of rapidly growing tumor cells, and there was lack of uptake in slowly growing and necrotic tumor areas. It is possible that TCP-1 uptake is associated with angiogenesis in the metabolically active tumor sites, but it appears to be different from Arg-Gly-Asp (RGD) targeting of integrin αvβ3 [27, 28] . Targeting of RGD peptide is independent of tumor type because integrin αvβ3 receptors are present at low levels in normal vasculature and upregulated during angiogenesis on all types of blood vessels [29, 30] . Increased permeability of tumor vasculature is not a major cause of increased of its renal reabsorption may be exploited to reduce the radioactivity in the kidneys [31, 32] .
Different 99m
Tc chelators as well as linking groups that affect the overall hydrophilicity and charge of the tracer may improve biodistribution. In future studies we will investigate whether the kidney uptake of 99m Tc-TCP-1 can be overcome by co-administration of cationic amino acids such as lysine or arginine [32] .
Current CRC diagnostic methods have lacked practical molecular imaging probes [7, 33, 34] .
SPECT imaging with 99m
Tc-TCP-1 may offer unique features relative to other CRC imaging methods such as immunoscintigraphy and 18 F-FDG PET imaging in discriminating early CRC lesions from inflammatory tissues [9] . Although radiolabeled antibodies or antibody fragments can target CRC primary tumor sites and metastases with high specificity and good predictive value [35] [36] [37] , there are drawbacks to the use of antibodies, including cost, immune response on repeat administration, suboptimal pharmacokinetics, and hepatobiliary excretion that results in high radioactive background in the intestine [35] . Some of these disadvantages can be overcome by using engineered or humanized antibody fragments. However, the utility of radiolabeled engineered antibody fragments for CRC diagnosis has not yet been clarified. PET imaging with 18 F-FDG is widely used for staging CRC and detecting recurrent or metastatic CRC sites [38, 39] . However, 18 F-FDG is taken up by all metabolically active cells and inflammatory tissues [9, 40] , making distinction difficult between inflammatory sites and tumors in the setting of bowel inflammation. Because of its small size and stable binding affinity, TCP-1 is expected to be able to penetrate tumor tissues and recognize targets more efficiently than antibodies. Tc-TCP-1 may reach clinically acceptable target-to-nontarget ratios quickly because of its rapid blood clearance and low uptake in liver and normal gastrointestinal tract, as shown by our data in this study. Moreover, unlike most molecular imaging probes that bind to receptors on the tumor cell surface, it is believed that the TCP-1-based probes may undergo endocytosis and distribute mainly in the nucleus [12, 13] , with the result that the probes may be retained longer than cellsurface ligands.
Our studies exploited the capability of DSWC to spatially co-register multiple parameters 
